{"id":408517,"date":"2025-11-27T14:34:28","date_gmt":"2025-11-27T14:34:28","guid":{"rendered":"https:\/\/www.europesays.com\/us\/408517\/"},"modified":"2025-11-27T14:34:28","modified_gmt":"2025-11-27T14:34:28","slug":"johnson-johnson-medtech-u-s-ortho-president-is-leaving","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/408517\/","title":{"rendered":"Johnson &#038; Johnson MedTech U.S. ortho president is leaving"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-109008\" src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/11\/Leslie-Storms-Johnson-Johnson-MedTech-300x195.jpg\" alt=\"Leslie Storms Johnson &amp; Johnson MedTech\" width=\"300\" height=\"195\"  \/>Johnson &amp; Johnson MedTech President of U.S. Orthopaedics Leslie Storms. [Image from LinkedIn]<a href=\"https:\/\/www.massdevice.com\/tag\/johnson-johnson-medtech\/\" target=\"_blank\" rel=\"noopener nofollow\">Johnson &amp; Johnson MedTech<\/a>\u00a0<\/p>\n<p>            (NYSE: JNJ)<br \/>\n            +<br \/>\n         President of U.S. Orthopaedics Leslie Storms announced that she is leaving the company this month.<\/p>\n<p>On LinkedIn, Storms posted that she is departing the medtech giant after 18 years.<\/p>\n<p>\u201cI\u2019ve had the great fortune to work with amazing leaders and talented teams filled with people passionate about \u2018what\u2019 they do because they are passionate about \u2018who\u2019 they ultimately serve\u2014patients,\u201d Storms <a href=\"https:\/\/www.linkedin.com\/feed\/update\/urn:li:activity:7399237939785867266\/\" target=\"_blank\" rel=\"noopener nofollow\">wrote<\/a>. \u201cI\u2019ve had the great fortune to work for a company that has helped me grow, challenged me to think differently, urged me to bring expertise but also fresh eyes, and supported me and my family at every turn.\u201d<\/p>\n<p>This departure comes as J&amp;J looks to separate its DePuy Synthes Orthopaedics business, <a href=\"https:\/\/www.massdevice.com\/johnson-johnson-separate-orthopedics-business\/\" target=\"_blank\" rel=\"noopener nofollow\">announcing the decision last month<\/a>. The company said the separation aims to enhance the strategic and operational focus of each company while driving stakeholder value. (<a href=\"https:\/\/www.massdevice.com\/johnson-johnson-medtech-schmid-acquisitions-opportunities\/\" target=\"_blank\" rel=\"noopener nofollow\">Tim Schmid<\/a>, J&amp;J MedTech\u2019s EVP and worldwide chair, <a href=\"https:\/\/www.massdevice.com\/johnson-johnson-medtech-chair-schmid-robotics-portfolio-realignment-will-define-next-growth-phase\/\" target=\"_blank\" rel=\"noopener nofollow\">spoke about this decision at DeviceTalks West last month<\/a>.)<\/p>\n<p>According to LinkedIn, Storms began her career at J&amp;J as VP of global sales &amp; marketing at its Noramco active pharmaceutical ingredients (API) manufacturing unit, which it eventually sold in 2016. In 2013, she became a senior marketing director for CNS within the company\u2019s Janssen unit.<\/p>\n<p>Storms moved to J&amp;J Vision, holding multiple VP roles there for three years before switching to the company\u2019s MedTech unit. She became VP of sales for Surgery, then president of sales for Surgery, before taking over as president of Orthopaedics in 2023.<\/p>\n<p>\u201cI leave J&amp;J with tremendous gratitude and \u2018prepped\u2019 for my next chapter,\u201d Storms wrote. \u201cWishing you all the best and we\u2019ll chat again soon.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Johnson &amp; Johnson MedTech President of U.S. Orthopaedics Leslie Storms. [Image from LinkedIn]Johnson &amp; Johnson MedTech\u00a0 (NYSE: JNJ)&hellip;\n","protected":false},"author":3,"featured_media":408518,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[210,1141,1142,1876,192416,192417,67,132,68],"class_list":{"0":"post-408517","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health-care","8":"tag-health","9":"tag-health-care","10":"tag-healthcare","11":"tag-johnson-johnson","12":"tag-johnson-johnson-medtech","13":"tag-personnel-moves","14":"tag-united-states","15":"tag-unitedstates","16":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115622161582276089","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/408517","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=408517"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/408517\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/408518"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=408517"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=408517"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=408517"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}